Analyst firms · Piper Sandler · SLDB

Piper Sandler SLDB price target and rating history

Solid Biosciences Inc. (SLDB) · Health Care

Piper Sandler rates Solid Biosciences Inc. (SLDB) Overweight with a $20 price target, as of its latest action on May 31, 2024. It has published 3 rating actions on SLDB since July 2021, including 1 upgrade and 0 downgrades. Across 5 firms with a SLDB price target in the last 12 months, the median target is $20.

Current rating
Overweight
Price target
$20
Median target, all firms
$20
Actions on SLDB
3

Piper Sandler price target on SLDB

$20$13$620222023202420252026
Piper Sandler price target on SLDB, each point a stated target, July 2021 to May 2024.

Every Piper Sandler rating on SLDB

How other firms rate SLDB

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
William BlairOutperformNov 9, 2026
UBSBuy$20Oct 15, 2026
RBC Capital MarketsOutperform$18Sep 16, 2026
Truist SecuritiesBuy$20Aug 21, 2026
GuggenheimBuy$26Mar 20, 2026
NeedhamBuy$16Dec 4, 2025

Questions about Piper Sandler and SLDB

What is Piper Sandler's price target for SLDB?
Piper Sandler's latest stated price target for Solid Biosciences Inc. (SLDB) is $20, from its action on May 31, 2024.
What is Piper Sandler's rating on SLDB?
Piper Sandler rates SLDB Overweight, a bullish rating, as of May 31, 2024.
When did Piper Sandler last change its view on SLDB?
On May 31, 2024, Piper Sandler resumes coverage at Overweight, price target $20.
How does Piper Sandler's SLDB target compare with other analysts?
Across 5 firms with a SLDB price target in the last 12 months, the median target is $20.

All Piper Sandler ratingsSLDB news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.